Skip to main content
PMC home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1995 Jan;114(2):475–481. doi: 10.1111/j.1476-5381.1995.tb13251.x

Pharmacological and biochemical analysis of FPL 67156, a novel, selective inhibitor of ecto-ATPase.

B E Crack 1, C E Pollard 1, M W Beukers 1, S M Roberts 1, S F Hunt 1, A H Ingall 1, K C McKechnie 1, A P IJzerman 1, P Leff 1
PMCID: PMC1510226  PMID: 7533620

Abstract

1. FPL 67156 (6-N,N-diethyl-beta, gamma-dibromomethylene-D-ATP), is a newly synthesized analogue of ATP. 2. In a rabbit isolated tracheal epithelium preparation, measuring P2U-purinoceptor-dependent chloride secretion, FPL 67156 was discovered to potentiate the responses to UTP but not those to ATP-gamma-S. UTP agonist-concentration effect (E/[A]) curves were shifted to the left by 5-fold in the presence of 100 microM FPL 67156. The differential effect of FPL 67156 on UTP and ATP-gamma-S was hypothesized to be due to the greater susceptibility of UTP to enzymatic dephosphorylation and the ability of FPL 67156 to inhibit this process. 3. FPL 67156 was tested as an ecto-ATPase inhibitor in a human blood cell assay, measuring [gamma 32P]-ATP dephosphorylation. The compound inhibited [gamma 32P]-ATP degradation with a pIC50 of 4.6. 4. FPL 67156 was then tested for its effects on ATP and alpha, beta-methylene-ATP responses at P2X-purinoceptors in the rabbit isolated ear artery. In the concentration range 30 microM-1 mM, the compound potentiated the contractile effects of ATP but not those of alpha, beta-methylene-ATP. At 1 mM, FPL 67156 produced a 34-fold leftward shift of ATP E/[A] curves. 5. The effects of FPL 67156 on ATP E/[A] curves in the rabbit ear artery were analyzed using a theoretical model (Furchgott, 1972) describing the action of an enzyme inhibitor on the effects of a metabolically unstable agonist. This analysis provided an estimate of the pKi for FPL 67156 as an ecto-ATPase inhibitor of 5.2.(ABSTRACT TRUNCATED AT 250 WORDS)

Full text

PDF
475

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Beukers M. W., Pirovano I. M., van Weert A., Kerkhof C. J., IJzerman A. P., Soudijn W. Characterization of ecto-ATPase on human blood cells. A physiological role in platelet aggregation? Biochem Pharmacol. 1993 Dec 3;46(11):1959–1966. doi: 10.1016/0006-2952(93)90637-c. [DOI] [PubMed] [Google Scholar]
  2. Burnstock G., Kennedy C. Is there a basis for distinguishing two types of P2-purinoceptor? Gen Pharmacol. 1985;16(5):433–440. doi: 10.1016/0306-3623(85)90001-1. [DOI] [PubMed] [Google Scholar]
  3. Foster R. W. The potentiation of the responses to noradrenaline and isoprenaline of the guinea-pig isolated tracheal chain preparation by desipramine, cocaine, phentolamine, phenoxybenzamine, guanethidine, metanephrine and cooling. Br J Pharmacol Chemother. 1967 Nov;31(3):466–482. doi: 10.1111/j.1476-5381.1967.tb00412.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Green A. L., Lord J. A., Marshall I. G. The relationship between cholinesterase inhibition in the chick biventer cervicis muscle and its sensitivity to exogenous acetylcholine. J Pharm Pharmacol. 1978 Jul;30(7):426–431. doi: 10.1111/j.2042-7158.1978.tb13279.x. [DOI] [PubMed] [Google Scholar]
  5. Humphries R. G., Tomlinson W., Ingall A. H., Cage P. A., Leff P. FPL 66096: a novel, highly potent and selective antagonist at human platelet P2T-purinoceptors. Br J Pharmacol. 1994 Nov;113(3):1057–1063. doi: 10.1111/j.1476-5381.1994.tb17100.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Kenakin T. P. Errors in the measurement of agonist potency-ratios produced by uptake processes: a general model applied to beta-adrenoceptor agonists. Br J Pharmacol. 1980;71(2):407–417. doi: 10.1111/j.1476-5381.1980.tb10953.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Leff P., Wood B. E., O'Connor S. E., McKechnie K. Quantitative analysis of the agonist and antagonist actions of some ATP analogues at P2X-purinoceptors in the rabbit ear artery. Br J Pharmacol. 1993 Feb;108(2):490–496. doi: 10.1111/j.1476-5381.1993.tb12830.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Leff P., Wood B. E., O'Connor S. E. Suramin is a slowly-equilibrating but competitive antagonist at P2x-receptors in the rabbit isolated ear artery. Br J Pharmacol. 1990 Nov;101(3):645–649. doi: 10.1111/j.1476-5381.1990.tb14134.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. O'Connor S. E., Wood B. E., Leff P. Characterization of P2x-receptors in rabbit isolated ear artery. Br J Pharmacol. 1990 Nov;101(3):640–644. doi: 10.1111/j.1476-5381.1990.tb14133.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Pöch G., Holzmann S. Quantitative estimation of overadditive and underadditive drug effects by means of theoretical, additive dose-response curves. J Pharmacol Methods. 1980 Sep;4(2):179–188. doi: 10.1016/0160-5402(80)90036-4. [DOI] [PubMed] [Google Scholar]
  11. Satchell D. Purine receptors in trachea: studies with adenosine deaminase and dipyridamole. Eur J Pharmacol. 1984 Jul 20;102(3-4):545–548. doi: 10.1016/0014-2999(84)90579-x. [DOI] [PubMed] [Google Scholar]
  12. Welford L. A., Cusack N. J., Hourani S. M. ATP analogues and the guinea-pig taenia coli: a comparison of the structure-activity relationships of ectonucleotidases with those of the P2-purinoceptor. Eur J Pharmacol. 1986 Oct 7;129(3):217–224. doi: 10.1016/0014-2999(86)90431-0. [DOI] [PubMed] [Google Scholar]
  13. Welford L. A., Cusack N. J., Hourani S. M. The structure-activity relationships of ectonucleotidases and of excitatory P2-purinoceptors: evidence that dephosphorylation of ATP analogues reduces pharmacological potency. Eur J Pharmacol. 1987 Sep 2;141(1):123–130. doi: 10.1016/0014-2999(87)90418-3. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES